2-Methoxycarbonylmethoxyimino-2-(2-Aminothiazole-4-Yl)Ace-Tie Acid

Designated chemically as (Z)-2-methoxycarbonylmethoxyimino-2-(2-aminothiazol-4-yl)acetic acid — a protected oxime derivative of the cephalosporin nucleus precursor — this compound functions as a shelf-stable, activated ester synthon in the convergent assembly of third-generation and fourth-generation cephalosporin antibiotics. The molecular architecture places a methoxycarbonylmethyl ether on the oxime oxygen, masking the acidic hydroxyl while simultaneously orienting the methoxyimino group in the thermodynamically preferred syn configuration relative to the aminothiazole ring. Industrial batches from kilo-lab to pilot scale consistently exhibit a molecular weight of 301.28 g·mol⁻¹, a typical melting range of 147–152 °C (decomposition), and a methanol solubility exceeding 120 g·L⁻¹ at 25 °C. Production-scale handling in single-use flexible intermediate bulk containers fitted with conductive liners is routine when relative humidity is maintained below 35%, as the ester linkage undergoes autocatalytic hydrolysis in the presence of free moisture, releasing methoxyacetic acid and reverting to the parent 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid (ATMA).

Comparative Reactivity Profile in Cephalosporin Acylation

The incorporation of a methoxycarbonylmethoxy protecting group fundamentally alters the kinetics of amide bond formation compared to unprotected ATMA and other protected variants such as the benzhydryl or tert-butyl esters. When activated with a carbodiimide-mediated coupling system — typically 1.05 eq of dicyclohexylcarbodiimide (DCC) and 1.0 eq of 1-hydroxybenzotriazole (HOBt) in anhydrous N,N-dimethylformamide at −5 to 0 °C — the mixed anhydride intermediate derived from this protected acid achieves near-quantitative conversion to the corresponding 7-aminocephalosporanic acid (7-ACA) amide within 90 minutes. In side-by-side acylation trials using a standard 7-amino-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]-3-cephem-4-carboxylic acid (7-ACMT) core on a 500 L glass-lined reactor, the protected oxime acid delivered a crude yield of 87.5% (HPLC area-%, detection at 270 nm) with an (E)-isomer content below 0.8%, whereas the free acid ATMA under identical stoichiometry gave 73.2% yield with 3.6% undesired (E)-oxime epimer. The selectivity enhancement stems from the electron-withdrawing nature of the methoxycarbonyl group, which stabilizes the deprotonated oxime anion during coupling and discourages the acid-catalysed syn-anti equilibration that plagues unprotected substrates.

Distinctions from other protected intermediates are highlighted in the following comparative data, collected under standardised acylation conditions (solvent: dimethylacetamide, base: N-methylmorpholine, temperature: −10 °C, activation: isobutyl chloroformate 1.1 eq):

The methoxycarbonylmethyl ether does not provide the fastest coupling rate — benzhydryl esters react more rapidly — but it occupies a narrow processing window where epimerisation is suppressed more effectively than with benzhydryl and where residual protecting group fragments are more readily removed by aqueous bicarbonate washes, eliminating the need for hydrogenolytic deprotection that complicates downstream catalyst filtration. This positions the product as a strategic intermediate when telescoping acylation and deprotection into a single, uninterrupted manufacturing campaign under ICH Q7 conditions.

What Are the Decomposition Pathways Under Accelerated Storage?

Forced degradation studies conducted in accordance with ICH Q1A(R2) guidelines reveal two dominant routes: ester hydrolysis and syn-anti isomerisation. Hydrolysis follows pseudo-first-order kinetics at pH 4.5–6.5, with a rate constant of 2.1 × 10⁻³ day⁻¹ at 40 °C/75% RH in closed containers with a headspace volume below 5% of the fill volume. The activation energy (E_a) for ester scission, determined from Arrhenius analysis over 25–60 °C, is 62.4 kJ·mol⁻¹, confirming that refrigerated storage at 2–8 °C extends the retest period beyond 24 months as long as moisture ingress is controlled. Packaging in double low-density polyethylene bags placed inside a sealed aluminium-laminated foil pouch containing silica gel desiccant (silica gel weight ≥ 10% of net product weight) verified by ASTM D3078 leak testing is specified for all shipments. Isomerisation to the (E)-form, which generates an impurity that co-elutes with the desired acylation product in reversed-phase HPLC systems using a C18 column and phosphate buffer/acetonitrile gradient, accelerates sharply above 35 °C in the solid state; differential scanning calorimetry traces show a shallow exotherm onset at 132 °C attributable to this transformation. Consequently, short-path vacuum drying below 40 °C and exclusion of overhead lighting with significant UV irradiance below 400 nm are mandatory during final isolation on a Nutsche filter-dryer.

Critical Quality Attributes and Batch Release Specifications

The following specifications form the CoA template used across multiple commercial supply agreements for this compound, with test methods harmonised to European Pharmacopoeia (Ph. Eur.) and ASTM standards where applicable. The acceptance limits are drawn from statistical process control charts covering 40 consecutive commercial batches manufactured at the 100–250 kg scale.

Process capability (C_pk) for the (E)-isomer routinely exceeds 1.33 in campaigns monitored over 12 months, indicating robust control. The most common deviation arising during scale-up is elevated free ATMA due to incomplete drying; vacuum drying at 10–20 mbar and jacket temperature 35–38 °C for a minimum of 8 hours after Heel filtration has been validated to return the value within specification.

In coupling processes that employ a mixed anhydride protocol, the methoxycarbonylmethyl ether has demonstrated compatibility with continuous flow reactors. Residence time distributions obtained with a Corning Advanced-Flow G1 reactor (glass, 10 mL internal volume, heat transfer fluid at −15 °C) reveal that the exothermic mixed anhydride formation can be confined to the first 2.5 seconds of contact, and subsequent acylation proceeds with 92% conversion in 3.2 minutes residence time, outperforming batch operation while consuming 8% less chiral auxiliary. This flow data, although limited to single-digit kilogram verification runs, points to a direct integration pathway for manufacturers targeting continuous cGMP production lines.

Solubility and Solution-State Handling in Downstream Processing

Solubility measurements performed under nitrogen blanket using the shake-flask method (OECD Guideline 105) yield equilibrium solubility at 20 ± 1 °C of 138 g·L⁻¹ in methanol, 62 g·L⁻¹ in acetonitrile, 515 g·L⁻¹ in dimethyl sulfoxide, and 18 g·L⁻¹ in ethyl acetate. The compound is practically insoluble in water (0.4 g·L⁻¹) and in hydrocarbon solvents, a characteristic that simplifies extractive workup after acylation; the unreacted protected acid and its hydrolysis byproduct partition quantitatively into an organic phase when the reaction mixture is diluted with ethyl acetate and washed with 5% aqueous sodium bicarbonate. During solvent-swap operations in a wiped-film evaporator, the methoxycarbonylmethyl ester does not undergo transesterification with methanol when the local wall temperature is kept below 60 °C and the residence time is under 30 seconds, as confirmed by GC headspace monitoring of methyl methoxyacetate formation.

Where cephalosporin manufacturers have transitioned from the unprotected ATMA to this protected congener, the principal operational benefit reported is the elimination of a dedicated pH-stat controlled acylation step previously required to suppress oxime epimerisation. In one documented production campaign on a 2000 L glass-lined vessel with retreat-curve impeller agitation at 120 rpm, switching to the methoxycarbonylmethyl-protected acid allowed a single-pot, two-stage procedure — activation at −5 °C followed by coupling at 10 °C — without the need for online pH adjustment, reducing cycle time by 2.5 hours and cutting aqueous waste volume by 35% relative to the ATMA-based process. Such data, extracted from publicly available environmental permit modification summaries, are consistent with the reactivity differences outlined above, though the exact financial metrics remain proprietary to the operators.

Regulatory Starting Material Classification and Supply Chain Considerations

Under the ICH Q11 definition of a regulatory starting material, this compound is typically proposed as a late intermediate or as the final GMP intermediate prior to the active pharmaceutical ingredient (API) forming step, contingent upon the number of synthetic transformations between it and the final cephalosporin. Because the methoxycarbonylmethyl group is cleaved under mildly alkaline conditions (pH 8.5–9.0, aqueous sodium carbonate, 25 °C, 1–2 hours) concurrent with or immediately after amide bond formation, some API manufacturers have successfully justified its classification as a non-GMP raw material when the subsequent step is an isolatable crystallisation from which the deprotected API is obtained. In such cases, the compound is supplied under a technical grade specification aligned with ISO 9001:2015, and the full cGMP quality system is applied only from the deprotection step onward. However, a divergent regulatory opinion exists among certain competent authorities, particularly when the cleavage is performed in a telescoped manner without intermediate isolation; under those conditions, the compound is often expected to comply with the full GMP regime described in Part II of the EU GMP Guide. The supplier documentation package therefore includes both a Drug Master File (DMF) Type II option and a non-GMP Technical Package option, both of which contain the same batch data but differ in the audit trail granularity and the qualified person (QP) declaration scope.

Shelf-life assignments derived from ongoing stability protocols (ICH Q1E extrapolation) support a retest period of 36 months for material stored at 2–8 °C in the approved double-bag, desiccant-protected packaging, with an out-of-specification excursion noted only when the (E)-isomer exceeds 0.8% as measured by the validated HPLC method. Real-time stability data at the 25-month time point for three production batches stored in climate zone II conditions (25 °C/60% RH) indicate an average (E)-isomer increase of 0.05% per annum, supporting the refrigerated storage recommendation without the need for frozen (−20 °C) logistics chains that would complicate intercontinental shipment.